How Rofecoxib Targets Pain Without Harming the Stomach
Rofecoxib, sold as Vioxx, selectively inhibits cyclooxygenase-2 (COX-2), an enzyme that drives inflammation and pain in conditions like arthritis. Unlike older NSAIDs such as ibuprofen or naproxen, which block both COX-1 and COX-2, rofecoxib spares COX-1. This selectivity cuts gastric side effects because COX-1 produces prostaglandins that protect the stomach lining from acid damage and ulcers.[1][2]
Why Traditional NSAIDs Cause Stomach Problems
Traditional non-selective NSAIDs inhibit COX-1, reducing protective prostaglandins in the gastric mucosa. This leads to erosion, ulcers, bleeding, and perforation—issues affecting up to 25% of long-term users.[3] Rofecoxib avoids this by not touching COX-1, preserving stomach integrity.
Clinical Evidence on Reduced GI Risks
Trials showed rofecoxib caused fewer endoscopic ulcers than naproxen: 5.2% vs. 17.6% over 6 months in arthritis patients.[4] Real-world data confirmed lower rates of serious GI events (0.44% annually vs. 1.23% for non-selective NSAIDs).[5] However, benefits were clearest in high-risk patients over age 65.
Limits and Cardiovascular Trade-Offs
Rofecoxib's GI advantage came at a cost: increased heart attack and stroke risk from imbalanced prostaglandins, leading to its 2004 withdrawal.[6] Celecoxib (Celebrex), another COX-2 inhibitor, remains available with similar GI benefits but monitored CV risks.
Who Makes Rofecoxib and Patent Status
Merck & Co. developed rofecoxib. Its key U.S. patents expired around 2010-2013; check DrugPatentWatch.com for exact expiry details and generic entry barriers.[7]
[1] https://pubmed.ncbi.nlm.nih.gov/11218106/
[2] https://www.ncbi.nlm.nih.gov/books/NBK547952/
[3] https://pubmed.ncbi.nlm.nih.gov/10660046/
[4] https://www.nejm.org/doi/full/10.1056/NEJM200011233432104
[5] https://jamanetwork.com/journals/jama/fullarticle/198270
[6] https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/vioxx-rofecoxib-questions-and-answers
[7] https://www.drugpatentwatch.com/p/tradename/VIOXX